Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

55514

Sigma-Aldrich

BioStab Antibody Stabilizer

Synonyme(s) :

Antibody Stabilizer BioStab

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Code UNSPSC :
12352204
Nomenclature NACRES :
NA.25

Technique(s)

HPLC: suitable

Niveau de qualité

100

Impuretés

DNases, none detected
 RNases, none detected
 phosphatases, none detected
 proteases, none detected

Adéquation

corresponds for identity (HPLC)

Température de stockage

2-8°C

Application

Antibodies can be protected from degradation effects using BioStab Antibody Stabilizer. The addition of BioStab Antibody Stabilizer increases life-time and the coating rates of the antibodies. BioStab Antibody Stabilizer can be used in ELISA, Western Blotting, Immunohistochemistry and any other applications which require marker or biotinylated antibodies. This stabilizer contains a minimum amount of a surfactant.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

Eyeshields, Gloves, type N95 (US)

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Jarem Edwards et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 25(11), 3247-3258 (2019-02-20)
Immunotherapies targeting costimulating and coinhibitory checkpoint receptors beyond PD-1 and CTLA-4 have entered clinical trials. Little is known about the relative abundance, coexpression, and immune cells enriched for each specific drug target, limiting understanding of the biological basis of potential
E Ron et al.
Journal of immunological methods, 180(2), 237-245 (1995-03-27)
A two step simple procedure for antibody stabilization in soluble form was developed. The antibody is first treated with low molecular weight polyaldehyde (polyglutaraldehyde). Following removal of non-bound polyaldehyde the antibody-polyaldehyde conjugate is crosslinked by polyamine (alkyl amine derivative of
Tim Serno et al.
Advanced drug delivery reviews, 63(13), 1086-1106 (2011-09-13)
Aggregation is arguably the biggest challenge for the development of stable formulations and robust manufacturing processes of therapeutic proteins. In search of novel excipients inhibiting protein aggregation, cyclodextrins and their derivatives have been under examination for use in parenteral protein
Lakshman N Subbaraman et al.
Optometry and vision science : official publication of the American Academy of Optometry, 82(3), 209-214 (2005-03-16)
Lysozyme deposits extracted from lotrafilcon silicone hydrogel (SH) contact lens materials demonstrate a loss in total mass as a function of storage time when assessed by Western blotting. This loss represents a potential source of error when quantifying total lysozyme
Eduardo P Melo et al.
Current protein & peptide science, 11(8), 744-751 (2011-01-18)
Biomedical applications of osmolytes, including stabilization of protein-based pharmaceutics, preservation of living biological material and potential therapeutic prescription in vivo, are intimately related to the fact that osmolytes favour the native structure of proteins. The shift towards the native structure
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique